A Boston-based startup is pursuing an unorthodox approach to helping smokers quit—it's attempting to make the world's first successful nicotine vaccine.
The company, Selecta Biosciences, was cofounded by MIT engineer Robert Langer and Harvard immunologists Ulrich von Andrian and Omid Farokhzad. Its goal is to develop a treatment that deprives a smoker of the habit's addictive effects by inducing an immune response that can last several years.
To read the full, original article click on this link: Vaccine Could Stop Nicotine from Reaching the Brain - Technology Review
